Maxigesic approval positive for AFT Pharmaceuticals

Maxigesic approval positive for AFT Pharmaceuticals
AFT founder and managing director Hartley Atkinson. (Image: Supplied)
Tamara Poi-Ngawhika
 AFT Pharmaceuticals, the owner of Maxigesic, offers investors a “large opportunity but with a high degree of uncertainty”, according to Forsyth Barr analysts.The New Zealand stock exchange-listed company has just announced its rapid-release tablet form of Maxigesic has been granted approval by the United States Food and Drug Administration (FDA) for use in the country.Breaking into the US market is difficult because getting FDA approval can be challenging. AFT said the US market is worth about US$7.16 billion (NZ$11.5b) and is...

More Markets

NZ stocks end lower while Eroad tanks
Markets Market Close

NZ stocks end lower while Eroad tanks

The S&P/NZX 50 Index dropped 99.89 points or 0.75% to 13,289.21.

Jamie Gray 17 Oct 2025
Macpac NZ profits drop 71% as softer sales hit margins
Retail

Macpac NZ profits drop 71% as softer sales hit margins

The sales drop in New Zealand was larger than Kathmandu's.

Gregor Thompson 17 Oct 2025
Eroad shares slump 23% as it shifts focus from North America
Markets

Eroad shares slump 23% as it shifts focus from North America

Eroad cuts North America exposure, impairing $150m in assets.

Rebecca Howard 17 Oct 2025
$55m deal secures Santana mining land
Primary Sector

$55m deal secures Santana mining land

The gold miner now owns all the land where its best mining prospects lie.  

Pattrick Smellie 17 Oct 2025